Cooper Companies Inc (NYSE:COO) Expected to Announce Earnings of $2.79 Per Share

Wall Street brokerages expect Cooper Companies Inc (NYSE:COO) to post $2.79 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Cooper Companies’ earnings. The lowest EPS estimate is $2.70 and the highest is $3.07. Cooper Companies posted earnings per share of $2.88 in the same quarter last year, which would indicate a negative year-over-year growth rate of 3.1%. The company is scheduled to announce its next earnings results on Tuesday, March 3rd.

On average, analysts expect that Cooper Companies will report full-year earnings of $12.99 per share for the current financial year, with EPS estimates ranging from $12.76 to $13.26. For the next fiscal year, analysts anticipate that the company will post earnings of $14.37 per share, with EPS estimates ranging from $14.07 to $14.80. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Cooper Companies.

Cooper Companies (NYSE:COO) last posted its earnings results on Thursday, December 5th. The medical device company reported $3.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.27 by $0.03. Cooper Companies had a net margin of 17.08% and a return on equity of 17.15%. The business had revenue of $691.60 million for the quarter, compared to analyst estimates of $683.83 million. During the same period in the prior year, the company posted $2.87 EPS. The company’s revenue for the quarter was up 6.2% on a year-over-year basis.

Several brokerages recently commented on COO. Raymond James dropped their price target on Cooper Companies from $364.00 to $355.00 and set an “in-line” rating for the company in a research report on Friday. Northcoast Research restated a “buy” rating on shares of Cooper Companies in a report on Tuesday. Zacks Investment Research raised Cooper Companies from a “sell” rating to a “hold” rating and set a $325.00 target price for the company in a research note on Wednesday, November 20th. Jefferies Financial Group reduced their price target on Cooper Companies from $358.00 to $330.00 and set an “in-line” rating on the stock in a report on Wednesday. Finally, KeyCorp boosted their price target on shares of Cooper Companies from $348.00 to $351.00 and gave the company an “overweight” rating in a research report on Wednesday, November 27th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the company’s stock. Cooper Companies presently has an average rating of “Buy” and an average target price of $324.83.

In related news, Director Allan E. Rubenstein sold 1,335 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $299.61, for a total value of $399,979.35. Following the completion of the transaction, the director now directly owns 3,591 shares in the company, valued at $1,075,899.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.70% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Commonwealth Equity Services LLC boosted its stake in Cooper Companies by 1.8% during the second quarter. Commonwealth Equity Services LLC now owns 3,650 shares of the medical device company’s stock worth $1,229,000 after buying an additional 66 shares during the period. Flagship Harbor Advisors LLC increased its position in shares of Cooper Companies by 62.5% during the second quarter. Flagship Harbor Advisors LLC now owns 78 shares of the medical device company’s stock valued at $26,000 after acquiring an additional 30 shares during the last quarter. Whittier Trust Co. acquired a new stake in shares of Cooper Companies during the second quarter valued at about $53,000. Commerzbank Aktiengesellschaft FI raised its stake in shares of Cooper Companies by 74.3% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 3,523 shares of the medical device company’s stock valued at $1,187,000 after acquiring an additional 1,502 shares during the period. Finally, Arden Trust Co purchased a new stake in shares of Cooper Companies in the 2nd quarter valued at approximately $205,000. Hedge funds and other institutional investors own 95.35% of the company’s stock.

NYSE:COO traded down $5.67 during trading hours on Monday, reaching $307.19. 741,150 shares of the company were exchanged, compared to its average volume of 321,306. The firm has a market cap of $15.47 billion, a PE ratio of 26.71, a price-to-earnings-growth ratio of 2.31 and a beta of 0.91. Cooper Companies has a twelve month low of $228.65 and a twelve month high of $344.32. The stock’s 50-day moving average is $298.29 and its 200-day moving average is $312.06. The company has a current ratio of 1.29, a quick ratio of 0.73 and a debt-to-equity ratio of 0.39.

About Cooper Companies

The Cooper Companies, Inc operates as a medical device company worldwide. It operates through CooperVision and CooperSurgical business units. The company develops, manufactures, and markets a range of contact lenses, including spherical lenses, and toric and multifocal lenses that correct near- and farsightedness, as well as addresses various complex visual defects, such as astigmatism and presbyopia.

Featured Article: What does the Dow Jones Industrial Average (DJIA) measure?

Get a free copy of the Zacks research report on Cooper Companies (COO)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Cooper Companies (NYSE:COO)

Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with's FREE daily email newsletter.